作者机构：
[Xiao, Juan] Hengyang Normal Univ, Sch Math & Stat, Hengyang 421008, Peoples R China.;[Qiu, De-hua] Guangdong Univ Finance & Econ, Sch Math & Stat, Guangzhou 510320, Peoples R China.
通讯机构：
[Qiu, De-hua] G;Guangdong Univ Finance & Econ, Sch Math & Stat, Guangzhou 510320, Peoples R China.
关键词：
pairwise negative quadrant dependent (PNQD) random variable;strong law of large numbers;complete convergence;general moment condition
摘要：
Let {X, X-n,n >= 1} be a sequence of identically distributed pairwise negative quadrant dependent (PNQD) random variables and {a(n),n >= 1} be a sequence of positive constants witha(n)=f(n) andf(theta(k))/f(theta(k-1)) >=beta for all large positive integersk, where 1 <theta <=beta andf(x) > 0 (x >= 1) is a non-decreasing function on [b, +infinity) for someb >= 1. In this paper, we obtain the strong law of large numbers and complete convergence for the sequence {X, X-n,n >= 1}, which are equivalent to the general moment condition n-ary sumation Sigma P-infinity(n=1)(vertical bar X vertical bar>a(n))<infinity. Our results extend and improve the related known works in Baum and Katz [1], Chen at al. [3], and Sung [14].
作者机构：
[Xiao, Jie; Liu, Yunmei; Yu, Wenmei; Guo, Yu; Zhang, Qizhi; Li, Yang] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Inst Pharm & Pharmacol, Hengyang 421001, Peoples R China.;[He, Jun] Univ South China, Inst Chem & Chem Engn, Hengyang 421001, Peoples R China.;[Liu, Mengqin] Hengyang Normal Univ, Inst Chem & Mat Sci, Hengyang 421001, Peoples R China.
通讯机构：
[Liu, Yunmei; He, Jun] U;Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Inst Pharm & Pharmacol, Hengyang 421001, Peoples R China.;Univ South China, Inst Chem & Chem Engn, Hengyang 421001, Peoples R China.
关键词：
Anti-tumor;Drug target;Inhibitors of protein kinases;Quinazoline derivatives;Structure-activity relationship
摘要：
Quinazoline was originally utilized as an anti-tumor treatment, and its various derivatives can be directly extracted from plants. In recent years, protein kinases (PK) have been well recognized in the development of tumor drugs. Functionally, PK serves a vital role in the apoptosis, proliferation, differentiation, migration and cell cycle of tumor cells. Due to its good physicochemical properties, quinazoline skeleton, a superior type of PK inhibitor, has been extensively used in anti-tumor drug design. An increasing number of studies on quinazoline synthesis have been reported and used by different groups to effectively develop novel derivatives. Thus, several studies have been approved for the use of quinazoline derivatives as inhibitors of other kinases, including Src and histone deacetylase. The aim of the present review was to summarize the mechanism of quinazoline compounds as PK inhibitors, their biological structure-activity relationship such as the substituted quinazoline compounds with different functional groups in the apoptotic process, and their effect on the proliferation of tumor cells. The development of novel agents based on the antitumor functions of quinazoline molecular compounds may improve the clinical outcomes of the affected population, particularly in patients with cancer.
